XNAS
TXG
Market cap9.38bUSD
Oct 20, Last price
71.46USD
1D
0.04%
1Q
48.07%
IPO
33.71%
Name
10X Genomics Inc
Chart & performance
P/E
—
P/S
14.48
EPS
—
Vol. 1Y
74.99%
Shs. 5Y
4.28%
Rev. 5Y
16.55%
Div Yld LY
—
Div Yld TTM
—
Revenues
643m
+5.25%
Net income
-44m
L-76.16%
CFO
136m
+1,941.57%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Key people
John Stuelpnagel
Independent Chairman of the Board · since 2013
Benjamin Hindson
President, Co-Founder, Chief Scientific Officer, Director · since 2014
Serge Saxonov
Chief Executive Officer, Co-Founder, Director · since 2012
Adam Taich
Chief Financial Officer · since 2024
Randy Wu
General Counsel, Company Secretary · since 2026
Sridhar Kosaraju
Independent Director · since 2019
Alan Mateo
Independent Director · since 2024
Independent Director · since 2020
Independent Director · since 2019
Sarah Teichmann
Independent Director · since 2024
Legal address
c/o NATIONAL REGISTERED AGENTS, INC., 1209 ORANGE STREET
Wilmington, DE 19801
US
Wilmington, DE 19801
US
Headquarters
7068 Koll Center Parkway; Suite 401
Pleasanton, CA 94566
US
Pleasanton, CA 94566
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||